PCM
DNTH icon

Penserra Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Penserra Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-83
Closed -$9K – 1414
2021
Q3 		$9K Hold
83
– – ﹤0.01% 1367
2021
Q2 		$12K Buy
83
+15
+22% +$2.75K ﹤0.01% 1260
2021
Q1 		$12K Sell
68
-1
-1% -$168 ﹤0.01% 1012
2020
Q4 		$8K Buy
69
+43
+165% +$4.88K ﹤0.01% 949
2020
Q3 		$2K Buy
+26
New +$3.08K ﹤0.01% 906

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Penserra Capital Management's DNTH Position: Q4 2021 in Review

Penserra Capital Management sold out of Dianthus Therapeutics (DNTH) in Q4 2021, closing a stake of 83 shares — an estimated $9K sold.

Penserra Capital Management first reported a position in DNTH in Q3 2020 and held it in 5 quarters. The position peaked at $12K in Q2 2021. 94 funds tracked by Wall St. Rank hold DNTH as of Q4 2021.

  • Penserra Capital Management reported no remaining Dianthus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 83 Dianthus Therapeutics shares in Q4 2021, an estimated $9K.
  • Penserra Capital Management first reported a position in Dianthus Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Dianthus Therapeutics position peaked at $12K in Q2 2021.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.